Compugen (NASDAQ:CGEN – Get Free Report) issued its earnings results on Tuesday. The biotechnology company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.20), Zacks reports. Compugen had a return on equity of 2.61% and a net margin of 2.67%. The firm had revenue of $17.13 million for the quarter, compared to analyst estimates of $17.67 million. During the same quarter in the previous year, the firm posted ($0.11) EPS.
Compugen Stock Performance
Shares of CGEN stock traded down $0.10 during mid-day trading on Thursday, hitting $1.49. 506,251 shares of the stock were exchanged, compared to its average volume of 407,126. Compugen has a 12-month low of $0.58 and a 12-month high of $3.03. The stock has a market capitalization of $132.97 million, a price-to-earnings ratio of 74.50 and a beta of 2.64. The stock’s fifty day simple moving average is $1.76 and its two-hundred day simple moving average is $1.87.
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded shares of Compugen from a “hold” rating to a “buy” rating in a research note on Thursday, August 15th.
Compugen Company Profile
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Compugen
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Conference Calls and Individual Investors
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Insider Buying Explained: What Investors Need to Know
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
